Skip to Primary Navigation

Skip to main content

PMCPA concludes Gossamer Bio pre-license promotion breach investigation

Open medication bottle with green capsules
Photo: Spencer Platt/Getty Images

Kevin Kinsella

3 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The UK watchdog found the biopharma company did not comply with two clauses of the AMPI Code related to a seralutinib meeting display.

The UK’s Prescription Medicines Code of Practice Authority (PMCPA) issued the final resolution in its case pertaining to the nature of Gossamer Bio’s presence at a meeting for healthcare professionals.

The PMCPA case summary relates to multiple complaints allegedly in violation of the Association of the British Pharmaceutical

, , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience